The R-Pharm group of companies took part in the 73rd annual congress of American College of Cardiology, at which it presented data on gene activity in patients with idiopathic recurrent pericarditis who took part in the study of the original drug with the active substance “goflikicept”.
Idiopathic recurrent pericarditis (IRP) is a rare autoinflammatory disease. Interleukin (IL)-1α and IL-1β are the pivotal cytokines in the pathophysiology of acute pericarditis and its recurrence. We created a phase II/III study with a new IL-1 inhibitor-goflikicept in IRP.
Goflikicept (RPH 104) is a hybrid protein that selectively binds and inactivates both circulating IL-1ß and IL-1α. Goflikicept has the potential for the research of ST-segment elevation myocardial infarction (STEMI). To date, data have been obtained on its safety and effectiveness in idiopathic recurrent pericarditis. Research is also underway on the effectiveness and safety of goflikicept in familial Mediterranean fever, in the pathogenesis of which IL-1 plays a major role.
“Our study enables clinicians to better understand the pathogenesis and treatment options for idiopathic recurrent pericarditis – a rare, life-threatening, rapidly progressive disease that also affects young people of working age and, in the absence of pathogenetic treatment, leads to disability,” explains Mikhail Samsonov, medical director of “ R-Pharm.”
